1.
2.
3.
4.
5.
6.
7.
8.
9.
Statistics and reproducibility
All western blots and immunofluorescence were independently replicated three times to ensure reproducibility. The RNase assay experiment in Supplementary Fig. 5c, d was performed twice with similar
results observed. The rest of the experimental replicate numbers are
indicated in the figure legends. One-way ANOVA followed by
Bonferroni-Holm post hoc tests were performed for all statistical
analyses unless stated otherwise in the figure legends. All analyses
were performed using online website statistical calculator ASTATSA
2016 (https://www.astatsa.com/) or GraphPad Prism version 9.0.0 for
Nature Communications | (2023)14:203
10.
11.
12.
Lander, E. S. et al. Initial sequencing and analysis of the human
genome. Nature 409, 860–921 (2001).
Grimaldi, G., Skowronski, J. & Singer, M. F. Defining the beginning
and end of KpnI family segments. EMBO J. 3, 1753–1759 (1984).
Ostertag, E. M. & Kazazian, H. H. Twin priming: a proposed
mechanism for the creation of inversions in L1 retrotransposition.
Genome Res. 11, 2059–2065 (2001).
Richardson, S. R. et al. The influence of LINE-1 and SINE retrotransposons on mammalian genomes. Microbiol. Spectr. 3,
MDNA3-0061-2014 (2015).
Sassaman, D. M. et al. Many human L1 elements are capable of
retrotransposition. Nat. Genet. 16, 37–43 (1997).
Brouha, B. et al. Hot L1s account for the bulk of retrotransposition
in the human population. Proc. Natl Acad. Sci. USA 100,
5280–5285 (2003).
Beck, C. R. et al. LINE-1 retrotransposition activity in human genomes. Cell 141, 1159–1170 (2010).
Chuang, N. T. et al. Mutagenesis of human genomes by endogenous mobile elements on a population scale. Genome Res. 31,
2225–2235 (2021).
Scott, A. F. et al. Origin of the human L1 elements: proposed
progenitor genes deduced from a consensus DNA sequence.
Genomics 1, 113–125 (1987).
Dombroski, B. A., Mathias, S. L., Nanthakumar, E., Scott, A. F. &
Kazazian, H. H. Isolation of an active human transposable element.
Science 254, 1805–1808 (1991).
Martin, S. L. & Bushman, F. D. Nucleic acid Chaperone activity of
the ORF1 protein from the mouse LINE-1 retrotransposon. Mol.
Cell. Biol. 21, 467–475 (2001).
Khazina, E. et al. Trimeric structure and flexibility of the L1ORF1
protein in human L1 retrotransposition. Nat. Struct. Mol. Biol. 18,
1006–1014 (2011).
22
Article
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Hohjoh, H. & Singer, M. F. Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA. EMBO J. 15,
630–639 (1996).
Mathias, S. L., Scott, A. F., Kazazian, H. H., Boeke, J. D. & Gabriel, A.
Reverse transcriptase encoded by a human transposable element.
Science 254, 1808–1810 (1991).
́ F., Marañón, C., Olivares, M., Alonso, C. & López, M. C.
Martın,
Characterization of a non-long terminal repeat retrotransposon
cDNA (L1Tc) from trypanosoma cruzi: homology of the first ORF
with the Ape aamily of DNA repair enzymes. J. Mol. Biol. 247,
49–59 (1995).
Feng, Q., Moran, J. V., Kazazian, H. H. & Boeke, J. D. Human L1
retrotransposon encodes a conserved endonuclease required for
retrotransposition. Cell 87, 905–916 (1996).
Moran, J. V. et al. High frequency retrotransposition in cultured
mammalian cells. Cell 87, 917–927 (1996).
Luan, D. D., Korman, M. H., Jakubczak, J. L. & Eickbush, T. H.
Reverse transcription of R2Bm RNA is primed by a nick at the
chromosomal target site: a mechanism for non-LTR retrotransposition. Cell 72, 595–605 (1993).
Cost, G. J., Feng, Q., Jacquier, A. & Boeke, J. D. Human L1 element
target-primed reverse transcription in vitro. EMBO J. 21,
5899–5910 (2002).
Flasch, D. A. et al. Genome-wide de novo L1 retrotransposition
connects endonuclease activity with replication. Cell 177,
837–851.e28 (2019).
Swergold, G. D. Identification, characterization, and cell specificity of a human LINE-1 promoter. Mol. Cell. Biol. 10,
6718–6729 (1990).
Athanikar, J. N., Badge, R. M. & Moran, J. V. A YY1-binding site is
required for accurate human LINE-1 transcription initiation.
Nucleic Acids Res. 32, 3846–3855 (2004).
Olovnikov, I. A. et al. Key role of the internal 5′-UTR segment in the
transcription activity of the human L1 retrotransposon. Mol. Biol.
41, 453–458 (2007).
Esnault, C., Maestre, J. & Heidmann, T. Human LINE retrotransposons generate processed pseudogenes. Nat. Genet. 24,
363–367 (2000).
Wei, W. et al. Human L1 retrotransposition: cis preference
versus trans complementation. Mol. Cell. Biol. 21,
1429–1439 (2001).
Kulpa, D. A. & Moran, J. V. Ribonucleoprotein particle formation is
necessary but not sufficient for LINE-1 retrotransposition. Hum.
Mol. Genet. 14, 3237–3248 (2005).
Doucet, A. J., Wilusz, J. E., Miyoshi, T., Liu, Y. & Moran, J. V. A 3′
Poly(A) tract is required for LINE-1 retrotransposition. Mol. Cell 60,
728–741 (2015).
Kubo, S. et al. L1 retrotransposition in nondividing and primary
human somatic cells. Proc. Natl Acad. Sci. USA 103,
8036–8041 (2006).
Mita, P. et al. LINE-1 protein localization and functional dynamics
during the cell cycle. eLife 7, e30058 (2018).
Cost, G. J. & Boeke, J. D. Targeting of human retrotransposon
integration is directed by the specificity of the L1 endonuclease for
regions of unusual DNA structure. Biochemistry 37,
18081–18093 (1998).
Morrish, T. A. et al. DNA repair mediated by endonucleaseindependent LINE-1 retrotransposition. Nat. Genet. 31,
159–165 (2002).
Kulpa, D. A. & Moran, J. V. Cis-preferential LINE-1 reverse transcriptase activity in ribonucleoprotein particles. Nat. Struct. Mol.
Biol. 13, 655–660 (2006).
Gilbert, N., Lutz-Prigge, S. & Moran, J. V. Genomic deletions created upon LINE-1 retrotransposition. Cell 110, 315–325 (2002).
Nature Communications | (2023)14:203
https://doi.org/10.1038/s41467-022-35757-6
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
Gilbert, N., Lutz, S., Morrish, T. A. & Moran, J. V. Multiple fates of L1
retrotransposition intermediates in cultured human cells. Mol.
Cell. Biol. 25, 7780–7795 (2005).
Piskareva, O. & Schmatchenko, V. DNA polymerization by the
reverse transcriptase of the human L1 retrotransposon on its own
template in vitro. FEBS Lett. 580, 661–668 (2006).
Kazazian, H. H. et al. Haemophilia A resulting from de novo
insertion of L1 sequences represents a novel mechanism for
mutation in man. Nature 332, 164–166 (1988).
Beck, C. R., Garcia-Perez, J. L., Badge, R. M. & Moran, J. V. LINE-1
elements in structural variation and disease. Annu. Rev. Genomics
Hum. Genet. 12, 187–215 (2011).
Hancks, D. C. & Kazazian, H. H. Roles for retrotransposon insertions in human disease. Mob. DNA 7, 9 (2016).
Kazazian, H. H. & Moran, J. V. Mobile DNA in health and disease. N.
Engl. J. Med. 377, 361–370 (2017).
Mavragani, C. P. et al. Expression of long interspersed nuclear
element 1 retroelements and induction of type I interferon in
patients with systemic autoimmune disease. Arthritis Rheumatol.
Hoboken NJ 68, 2686–2696 (2016).
Li, P. et al. Aicardi–Goutières syndrome protein TREX1 suppresses
L1 and maintains genome integrity through exonucleaseindependent ORF1p depletion. Nucleic Acids Res. 45,
4619–4631 (2017).
Zhao, K. et al. LINE1 contributes to autoimmunity through both
RIG-I- and MDA5-mediated RNA sensing pathways. J. Autoimmun.
90, 105–115 (2018).
Cecco, M. D. et al. LINE-1 derepression in senescent cells triggers
interferon and inflammaging. Nature 566, 73–78 (2019).
Simon, M. et al. LINE1 derepression in aged wild-type and SIRT6deficient mice drives inflammation. Cell Metab. 29,
871–885.e5 (2019).
Ardeljan, D. et al. Cell fitness screens reveal a conflict between
LINE-1 retrotransposition and DNA replication. Nat. Struct. Mol.
Biol. 27, 168–178 (2020).
Tunbak, H. et al. The HUSH complex is a gatekeeper of type I
interferon through epigenetic regulation of LINE-1s. Nat. Commun.
11, 5387 (2020).
Anderson, P. & Kedersha, N. Stressful initiations. J. Cell Sci. 115,
3227–3234 (2002).
Goodier, J. L., Zhang, L., Vetter, M. R. & Kazazian, H. H. LINE-1 ORF1
protein localizes in stress granules with other RNA-binding
proteins, including components of RNA interference RNAinduced silencing complex. Mol. Cell. Biol. 27, 6469–6483
(2007).
Doucet, A. J. et al. Characterization of LINE-1 ribonucleoprotein
particles. PLoS Genet. 6, e1001150 (2010).
Moldovan, J. B. & Moran, J. V. The zinc-finger antiviral protein ZAP
inhibits LINE and Alu retrotransposition. PLOS Genet. 11,
e1005121 (2015).
Kedersha, N., Ivanov, P. & Anderson, P. Stress granules and cell
signaling: more than just a passing phase? Trends Biochem. Sci.
38, 494–506 (2013).
Protter, D. S. W. & Parker, R. Principles and properties of stress
granules. Trends Cell Biol. 26, 668–679 (2016).
Goodier, J. L., Cheung, L. E. & Kazazian, H. H. MOV10 RNA helicase
is a potent inhibitor of retrotransposition in cells. PLoS Genet. 8,
e1002941 (2012).
Goodier, J. L., Pereira, G. C., Cheung, L. E., Rose, R. J. & Kazazian, H.
H. The broad-spectrum antiviral protein ZAP restricts human retrotransposition. PLoS Genet. 11, e1005252 (2015).
Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and
integrative analysis of large gene lists using DAVID bioinformatics
resources. Nat. Protoc. 4, 44–57 (2009).
23
Article
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Sherman, B. T. et al. DAVID: a web server for functional enrichment
analysis and functional annotation of gene lists (2021 update).
Nucleic Acids Res. 50, W216–W221 (2022).
Subramanian, A. et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Kammerer, R. A. et al. A conserved trimerization motif controls the
topology of short coiled coils. Proc. Natl Acad. Sci. USA 102,
13891–13896 (2005).
Adney, E. M. et al. Comprehensive scanning mutagenesis of
human retrotransposon LINE-1 identifies motifs essential for
function. Genetics 213, 1401–1414 (2019).
Wei, W., Morrish, T. A., Alisch, R. S. & Moran, J. V. A transient assay
reveals that cultured human cells can accommodate multiple
LINE-1 retrotransposition events. Anal. Biochem. 284,
435–438 (2000).
Kopera, H. C. et al. LINE-1 cultured cell retrotransposition assay.
Methods Mol. Biol. Clifton NJ 1400, 139–156 (2016).
Tourrière, H. et al. The RasGAP-associated endoribonuclease
G3BP assembles stress granules. J. Cell Biol. 160, 823–831 (2003).
Briggs, E. M. et al. RIP-seq reveals LINE-1 ORF1p association with
p-body enriched mRNAs. Mob. DNA 12, 5 (2021).
Dai, L., Taylor, M. S., O’Donnell, K. A. & Boeke, J. D. Poly(A)
binding protein C1 is essential for efficient L1 retrotransposition
and affects L1 RNP formation. Mol. Cell. Biol. 32,
4323–4336 (2012).
Taylor, M. S. et al. Affinity proteomics reveals human host factors
implicated in discrete stages of LINE-1 retrotransposition. Cell 155,
1034–1048 (2013).
Tristán-Ramos, P. et al. The tumor suppressor microRNA let-7
inhibits human LINE-1 retrotransposition. Nat. Commun. 11,
5712 (2020).
Yu, Q. et al. Type I interferon controls propagation of long
interspersed element-1. J. Biol. Chem. 290, 10191–10199
(2015).
Arjan-Odedra, S., Swanson, C. M., Sherer, N. M., Wolinsky, S. M. &
Malim, M. H. Endogenous MOV10 inhibits the retrotransposition of
endogenous retroelements but not the replication of exogenous
retroviruses. Retrovirology 9, 53 (2012).
Li, X. et al. The MOV10 helicase inhibits LINE-1 mobility. J. Biol.
Chem. 288, 21148–21160 (2013).
Orecchini, E. et al. ADAR1 restricts LINE-1 retrotransposition.
Nucleic Acids Res. 45, 155–168 (2017).
Esnault, C. et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433,
430–433 (2005).
Bogerd, H. P. et al. Cellular inhibitors of long interspersed element
1 and Alu retrotransposition. Proc. Natl Acad. Sci. USA 103,
8780–8785 (2006).
Muckenfuss, H. et al. APOBEC3 proteins inhibit human LINE-1
retrotransposition. J. Biol. Chem. 281, 22161–22172 (2006).
Hulme, A. E., Bogerd, H. P., Cullen, B. R. & Moran, J. V. Selective
inhibition of Alu retrotransposition by APOBEC3G. Gene 390,
199–205 (2007).
Lovšin, N. & Peterlin, B. M. APOBEC3 proteins inhibit LINE-1 retrotransposition in the absence of ORF1p binding. Ann. N. Y. Acad.
Sci. 1178, 268–275 (2009).
Horn, A. V. et al. Human LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that
affects LINE reverse transcriptase activity. Nucleic Acids Res. 42,
396–416 (2014).
Richardson, S. R., Narvaiza, I., Planegger, R. A., Weitzman, M. D. &
Moran, J. V. APOBEC3A deaminates transiently exposed singlestrand DNA during LINE-1 retrotransposition. eLife 3,
e02008 (2014).
Nature Communications | (2023)14:203
https://doi.org/10.1038/s41467-022-35757-6
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
Feng, Y., Goubran, M. H., Follack, T. B. & Chelico, L. Deaminationindependent restriction of LINE-1 retrotransposition by APOBEC3H. Sci. Rep. 7, 10881 (2017).
Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134,
587–598 (2008).
Thomas, C. A. et al. Modeling of TREX1-dependent autoimmune
disease using human stem cells highlights L1 accumulation as a
source of neuroinflammation. Cell Stem Cell 21, 319–331.e8 (2017).
Zhao, K. et al. Modulation of LINE-1 and Alu/SVA retrotransposition
by Aicardi-Goutières syndrome-related SAMHD1. Cell Rep. 4,
1108–1115 (2013).
Hu, S. et al. SAMHD1 inhibits LINE-1 retrotransposition by promoting stress granule formation. PLoS Genet. 11, e1005367 (2015).
White, T. E. et al. Modulation of LINE-1 retrotransposition by a
human SAMHD1 polymorphism. Virol. Rep. 6, 53–60 (2016).
Benitez‐Guijarro, M. et al. RNase H2, mutated in Aicardi‐Goutières
syndrome, promotes LINE‐1 retrotransposition. EMBO J. 37,
e98506 (2018).
Choi, J., Hwang, S.-Y. & Ahn, K. Interplay between RNASEH2 and
MOV10 controls LINE-1 retrotransposition. Nucleic Acids Res. 46,
1912–1926 (2018).
Zhang, A. et al. RNase L restricts the mobility of engineered retrotransposons in cultured human cells. Nucleic Acids Res. 42,
3803–3820 (2014).
Rusinova, I. et al. INTERFEROME v2.0: an updated database of
annotated interferon-regulated genes. Nucleic Acids Res. 41,
D1040–D1046 (2013).
Szklarczyk, D. et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery
in genome-wide experimental datasets. Nucleic Acids Res. 47,
D607–D613 (2019).
Warkocki, Z. et al. Uridylation by TUT4/7 restricts retrotransposition of human LINE-1s. Cell 174, 1537–1548.e29 (2018).
Amblar, M., Barbas, A., Fialho, A. M. & Arraiano, C. M. Characterization of the functional domains of Escherichia coli RNase II. J.
Mol. Biol. 360, 921–933 (2006).
Frazão, C. et al. Unravelling the dynamics of RNA degradation by
ribonuclease II and its RNA-bound complex. Nature 443,
110–114 (2006).
Barbas, A. et al. New insights into the mechanism of RNA degradation by ribonuclease II: identification of the residue responsible
for setting the RNase II end product. J. Biol. Chem. 283,
13070–13076 (2008).
Walker, J. E., Saraste, M., Runswick, M. J. & Gay, N. J. Distantly
related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a
common nucleotide binding fold. EMBO J. 1, 945–951 (1982).
Finn, R. D. et al. Pfam: the protein families database. Nucleic Acids
Res. 42, D222–D230 (2014).
Miller, J. M. & Enemark, E. J. Fundamental characteristics of AAA+
protein family structure and function. Archaea 2016,
9294307 (2016).
Dewannieux, M., Esnault, C. & Heidmann, T. LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 35,
41–48 (2003).
Miyoshi, T., Makino, T. & Moran, J. V. Poly(ADP-Ribose) polymerase
2 recruits replication protein A to sites of LINE-1 integration to
facilitate retrotransposition. Mol. Cell 75, 1286–1298.e12 (2019).
Chu, L.-Y. et al. Structural insights into RNA unwinding and
degradation by RNase R. Nucleic Acids Res. 45,
12015–12024 (2017).
Reis, F. P., Pobre, V., Silva, I. J., Malecki, M. & Arraiano, C. M. The
RNase II/RNB family of exoribonucleases: putting the ‘Dis’ in disease. WIREs RNA 4, 607–615 (2013).
24
Article
100. Awano, N. et al. Escherichia coli RNase R has dual activities, helicase and RNase. J. Bacteriol. 192, 1344–1352 (2010).
101. Hossain, S. T., Malhotra, A. & Deutscher, M. P. The helicase activity
of ribonuclease R is essential for efficient nuclease activity. J. Biol.
Chem. 290, 15697–15706 (2015).
102. Naufer, M. N. et al. L1 retrotransposition requires rapid ORF1p oligomerization, a novel coiled coil-dependent property conserved
despite extensive remodeling. Nucleic Acids Res. 44,
281–293 (2016).
103. Bourc’his, D. & Bestor, T. H. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature 431, 96–99 (2004).
104. Coufal, N. G. et al. L1 retrotransposition in human neural progenitor cells. Nature 460, 1127–1131 (2009).
105. Ewing, A. D. et al. Nanopore sequencing enables comprehensive
transposable element epigenomic profiling. Mol. Cell 80,
915–928.e5 (2020).
106. Jacobs, F. M. J. et al. An evolutionary arms race between KRAB
zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons. Nature
516, 242–245 (2014).
107. Larson, P. A. et al. Spliced integrated retrotransposed element
(SpIRE) formation in the human genome. PLOS Biol. 16,
e2003067 (2018).
108. Surapureddi, S. et al. Identification of a transcriptionally active
peroxisome proliferator-activated receptor α-interacting cofactor
complex in rat liver and characterization of PRIC285 as a coactivator. Proc. Natl Acad. Sci. USA 99, 11836–11841 (2002).
109. Tomaru, T. et al. Isolation and characterization of a transcriptional
cofactor and its novel isoform that bind the deoxyribonucleic acidbinding domain of peroxisome proliferator-activated receptor-γ.
Endocrinology 147, 377–388 (2006).
110. Tchenio, T., Casella, J. F. & Heidmann, T. Members of the SRY
family regulate the human LINE retrotransposons. Nucleic Acids
Res. 28, 411–415 (2000).
111. Yang, N., Zhang, L., Zhang, Y. & Kazazian, H. H. An important role
for RUNX3 in human L1 transcription and retrotransposition.
Nucleic Acids Res. 31, 4929–4940 (2003).
112. Sun, X. et al. Transcription factor profiling reveals molecular
choreography and key regulators of human retrotransposon
expression. Proc. Natl Acad. Sci. USA 115, E5526–E5535 (2018).
113. Usdin, K. & Furano, A. V. The structure of the guanine-rich polypurine:polypyrimidine sequence at the right end of the rat L1
(LINE) element. J. Biol. Chem. 264, 15681–15687 (1989).
114. Crow, M. K. Long interspersed nuclear elements (LINE-1): potential
triggers of systemic autoimmune disease. Autoimmunity 43,
7–16 (2010).
115. Volkman, H. E. & Stetson, D. B. The enemy within: endogenous
retroelements and autoimmune disease. Nat. Immunol. 15,
415–422 (2014).
116. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens
in human cells using the CRISPR-Cas9 system. Science 343,
80–84 (2014).
117. Kopera, H. C., Moldovan, J. B., Morrish, T. A., Garcia-Perez, J. L. &
Moran, J. V. Similarities between long interspersed element-1
(LINE-1) reverse transcriptase and telomerase. Proc. Natl Acad. Sci.
USA 108, 20345–20350 (2011).
118. Kowarz, E., Löscher, D. & Marschalek, R. Optimized Sleeping
Beauty transposons rapidly generate stable transgenic cell lines.
Biotechnol. J. 10, 647–653 (2015).
119. Mátés, L. et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in
vertebrates. Nat. Genet. 41, 753–761 (2009).
Nature Communications | (2023)14:203
https://doi.org/10.1038/s41467-022-35757-6
120. Ostertag, E. M., Luning Prak, E. T., DeBerardinis, R. J., Moran,
J. V. & Kazazian, H. H. Determination of L1 retrotransposition
kinetics in cultured cells. Nucleic Acids Res. 28, 1418–1423
(2000).
121. Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for
researchers, educators, and developers. Protein Sci. 30,
70–82 (2021).
122. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to
ImageJ: 25 years of image analysis. Nat. Methods 9,
671–675 (2012).
Acknowledgements
We thank K. H. Burns, D. Ardeljan, T. Heidmann, M. T. Hayashi, D.
Trono, and Z. Izsvak for valuable reagents, all Ishikawa lab members
(especially Theventhiran, T. Makino, K. Sugino, and K. Nishimori), K.
Takahara, M. Miyoshi, and J. B. Moldovan for helpful discussions.
A.L.-F. was supported by JASSO and MEXT Scholarships. F.I. was
supported by JSPS KAKENHI (Grant Number JP19H05655). J.V.M.
was supported, in part, by NIH grant GM060518. T.M. was supported by JSPS KAKENHI (Grant Number JP18K06180 and 21K19219),
ISHIZUE 2021 of Kyoto University Research Development Programs,
and research grants from the Takeda Science Foundation, the Japan
Foundation for Applied Enzymology, the Sumitomo Foundation for
Basic Science Research Projects, and Astellas Foundation for
Research on Metabolic Disorders. A part of this study was conducted through the CORE Program of the Radiation Biology Center,
Kyoto University and was supported by the Core-to-Core
Program, JSPS.
Author contributions
A.L.-F., J.V.M., and T.M. conceived and designed the experiments, analyzed data, and prepared the manuscript. A.L.-F. and T.M. performed
experiments. Y.W. provided technical support and performed mass
spectrometry. K.U. conducted the Bio-Plex cytokine assay. F.I., J.V.M.,
and T.M. contributed to critical discussions, writing, and editing the
manuscript. All authors contributed to ideas.
Competing interests
J.V.M. is an inventor on patent US6150160, is a paid consultant for Gilead
Sciences, serves on the scientific advisory board to Tessera Therapeutics Inc. (where he is paid as a consultant and has equity options),
has licensed reagents to Merck Pharmaceutical, and recently served on
the American Society of Human Genetics Board of Directors. The other
authors declare no competing interests.
Additional information
Supplementary information The online version contains
supplementary material available at
https://doi.org/10.1038/s41467-022-35757-6.
Correspondence and requests for materials should be addressed to
Tomoichiro Miyoshi.
Peer review information Nature Communications thanks John LaCava
and the other, anonymous, reviewer(s) for their contribution to the peer
review of this work. Peer reviewer reports are available.
Reprints and permissions information is available at
http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
25
Article
https://doi.org/10.1038/s41467-022-35757-6
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2023, corrected publication 2023
Nature Communications | (2023)14:203
26
...
論文の公開元へ
